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Abstract
Following reports of an increased incidence of amyotrophic lateral sclerosis (ALS) in U.S. veterans, we have conducted a
high-density genome-wide association study (GWAS) of ALS outcome and survival time in a sample of U.S. veterans. We
tested ,1.3 million single nucleotide polymorphisms (SNPs) for association with ALS outcome in 442 incident Caucasian
veteran cases diagnosed with definite or probable ALS and 348 Caucasian veteran controls. To increase power, we also
included genotypes from 5909 publicly-available non-veteran controls in the analysis. In the survival analysis, we tested for
association between SNPs and post-diagnosis survival time in 639 Caucasian veteran cases with definite or probable ALS.
After this discovery phase, we performed follow-up genotyping of 299 SNPs in an independent replication sample of
Caucasian veterans and non-veterans (ALS outcome: 183 cases and 961 controls; survival: 118 cases). Although no SNPs
reached genome-wide significance in the discovery phase for either phenotype, three SNPs were statistically significant in
the replication analysis of ALS outcome: rs6080539 (177 kb from PCSK2), rs7000234 (4 kb from ZNF704), and rs3113494
(13 kb from LOC100506746). Two SNPs located in genes that were implicated by previous GWA studies of ALS were
marginally significant in the pooled analysis of discovery and replication samples: rs17174381 in DPP6 (p=4.4610
24) and
rs6985069 near ELP3 (p=4.8610
24). Our results underscore the difficulty of identifying and convincingly replicating genetic
associations with a rare and genetically heterogeneous disorder such as ALS, and suggest that common SNPs are unlikely to
account for a substantial proportion of patients affected by this devastating disorder.
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Amyotrophic lateral sclerosis (ALS) is a fatal disease character-
ized by motor neuron degeneration, which leads to muscle atrophy
and paralysis. Typically, this progressive muscle wasting results in
death from respiratory failure within 2–4 years after onset of
symptoms. ALS is the most common adult-onset motor neuron
disease, with an incidence of 2–3 cases per 100,000 person-years
[1], but its prevalence is low due to the poor prognosis associated
with disease.
The majority of ALS cases are sporadic; approximately 5% of
cases show a family history of disease [2]. Although several
causative genes have been identified in familial ALS, the genetic
contributors to sporadic ALS have been more difficult to identify.
Genome-wide association studies of sporadic ALS have implicated
a number of genes or regions (DPP6, ITPR2, UNC13A, FGGY,
ELP3, KIFAP3, 9p21.2) [3–11], but replication of these findings in
independent populations has proven difficult [12–16]. A possible
exception is the 9p21.2 region, which was recently replicated by
two large independent studies and seems to be important in both
familial and sporadic ALS [17,18].
Environmental exposures also appear to play a role in ALS
incidence. Some of the reported associations include cigarette
smoking [19,20], head injury [21–23], exposure to lead or other
heavy metals [24–27], exposure to pesticides [28,29], and
physical activity [30,31], although subsequent independent
studies have reported mixed results. Additionally, an increased
incidence of ALS has been reported both specifically for US
veterans of the Persian Gulf War [32–34] and more generally for
all US veterans [35]. The nature of the relationship between
military service and ALS merits further investigation into the
possible aspects of military service (environmental exposures,
deployment exposures, lifestyle behaviors) that may confer an
increased risk of ALS.
Here, we describe a genome-wide association study (GWAS)
performed in a population of US veterans. To our knowledge, this
is the first genome-wide study designed to identify genetic factors
that may contribute to ALS in a veteran population. Genotypes
were obtained using two different arrays, which generated the
highest density of single-nucleotide polymorphisms (SNPs) of all
ALS GWA studies published to date. Additionally, the existence of
overlapping probes on the two arrays allowed us to evaluate
genotype concordance between the platforms and to reduce
genotyping errors. In order to evaluate genetic factors associated
with developing sporadic ALS as well as survival time after
diagnosis of ALS, we performed both a case-control analysis and a
survival analysis. Following the discovery phase of the study, we
genotyped potentially-interesting SNPs in an independent repli-
cation study consisting of both veterans and non-veterans.
Methods
Ethics statement
This study was conducted in accordance with the Declaration of
Helsinki of the World Medical Association. All study participants
provided written informed consent. The research was reviewed
and approved by the Institutional Review Boards from all
participating institutions, including the Institutional Review
Boards of the Durham VA and Duke University Medical Centers,
the Parkinson’s Institute, National Institutes of Health, National
Institute of Environmental Health Sciences, University of Iowa,
Massachusetts General Hospital, New England Medical Center,
Brigham and Women’s Hospital, Social and Scientific Systems,
Inc., Battelle, Inc., Survey Research Associates, CODA, and the
Human Subject Committees of the Kaiser Foundation Research
Institute and Stanford University.
Participants
Case samples for this study were obtained from the National
Registry of Veterans with ALS, which enrolled 2121 US veterans
between April 2003 and September 2007. We refer to the veteran
cases here as ‘‘NRVA cases.’’ Methods for recruitment, medical
record review, and enrollment into the Registry have been
described in detail elsewhere [36]. Briefly, cases were actively
recruited through periodic searches of Veterans Administration
(VA) inpatient and outpatient databases for ICD-9 (International
Classification of Diseases, 9th Revision, Clinical Modification)
diagnoses of motor neuron disease. Passive recruitment methods
included the distribution of study brochures and mailings to ALS
specialty clinics and neurologists, along with links on ALS-related
websites. Following informed consent and enrollment, neurologists
reviewed each case’s medical records to confirm a diagnosis of
definite, probable or possible ALS according to the original El
Escorial criteria [37,38]. Patients were also enrolled in the Registry
if they had ‘‘suspected ALS’’ according to the criteria, which
included a diagnosis of progressive muscular atrophy (PMA),
primary lateral sclerosis (PLS) or progressive bulbar palsy (PBP). A
subset of enrollees (n=1173) consented to participate in the
registry-affiliated DNA bank and donated DNA via blood (84.6%)
or mouthwash (15.4%), and 1163 of these samples were available
for genotyping in this study. Registry enrollees were contacted for
follow-up telephone interviews every 6 months from enrollment
until September 30, 2009; the ALS Functional Rating Scale
(ALSFRS-R) was administered at each of the follow-up interviews.
The veteran controls described here were enrolled in the
‘‘Genes and Environmental Exposures in Veterans with ALS’’
(GENEVA) study. As described previously [39], controls were
identified from a database of US veterans maintained by the
Veterans Benefit Administration and recruited via mailings and
telephone calls. We refer to these controls as ‘‘GENEVA
controls.’’ Controls were frequency-matched to cases on age (in
5-year intervals), gender, and use of the VA for health care (prior
to diagnosis, for cases). Controls passed a telephone screener to
confirm the absence of ALS and other neurological diseases. All of
the GENEVA controls were administered telephone interviews
about environmental exposures, as was a subset of the sampled
NRVA cases (57%). Controls were also asked to donate a saliva
sample for DNA extraction and genotyping; 411 control samples
were genotyped in the discovery phase of this study. To improve
the statistical power of our discovery GWAS, we also made use of
approximately 6,000 publicly-available control genotypes gener-
ated by the same two high-density chips and distributed by the
Wellcome Trust Case Control Consortium (WTCCC2) (http://
www.wtccc.org.uk/ccc2/) [40]. Of these controls, 51.6% were
recruited from the 1958 British birth cohort; the remainder
comprised blood donors from the UK Blood Service Collection.
As previously demonstrated [41], publicly available controls are
well suited for inclusion into the analysis of a rare disease like ALS,
because they have a very low probability of misclassification.
The replication phase of this analysis included 490 additional
controls ascertained through the GENEVA study and 20 NRVA
cases along with samples from the Northeast ALS Consortium (52
cases and 11 controls, contributed by MEC); the Agricultural
Health Study (312 controls, contributed by FK); a New England
study of ALS (108 cases and 38 controls, contributed by FK); and
the Genetics and Epidemiology of Motor Neuron disease (GEM)
study (100 cases and 308 controls, contributed by LMN). Details of
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Methods S1.
Laboratory methods
For NRVA case samples, DNA was obtained from peripheral
blood or from buccal cells. Blood was collected in 10 ml EDTA
blood tubes. The blood was centrifuged for 15 min at 18506ga t
4uC; the plasma was removed and saved. The remaining buffy
coat and red cells were transferred to a tube for DNA extraction.
Buccal cells were collected in 10 ml original Mint Scope
Mouthwash (Proctor & Gamble). The samples were centrifuged
for 10 min at 20006g and the supernatant discarded. DNA from
both blood and buccal cells was extracted on an Autopure
instrument using Puregene reagents (Qiagen, Valencia, CA). A
subset of samples (1 blood; 16 buccal) did not have sufficient
DNA available for genotyping. For these samples, DNA
amplification was performed using the REPLI-g DNA amplifi-
cation kit (Qiagen, Valencia, CA) according to the manufactur-
er’s directions. Samples (20–50 ng) were amplified for 16 h and
then purified by alcohol precipitation. For veteran control
samples, DNA was extracted from Oragene samples (DNA
Genotek, Inc.) using the Autopure LX following the manufac-
turer’s recommended protocol.
Genotyping and quality control
The discovery samples were genotyped on the Affymetrix
Genome-Wide Human SNP Array 6.0 at Affymetrix, Inc. (Santa
Clara, CA) and the Illumina Human1M-Duo genotyping array at
the VA Pharmacogenomics Analysis Laboratory (Little Rock, AR).
After calling the genotypes (see Methods S2 for a detailed
description of the genotype-calling methods), we applied the
following set of quality control (QC) filters to the autosomal SNPs
on each array independently. We excluded SNPs with call
frequency ,98%, minor allele frequency #3%, HWE p-value
,10
26 in controls, heterozygote calls $65% and p-value ,10
25
for a test of differential missingness between cases and controls.
We also applied standard QC methods to the samples genotyped
on each array and removed samples based on call rate (,98%),
mismatch between self-reported gender and genotypic gender,
cryptic relatedness between samples, or outlying ethnicity (see
Methods S3 and Table S1 for details). After applying these QC
filters, our discovery sample contained 1142 cases (98.2%) and 394
controls (95.9%) with data from at least one genotyping array
(Illumina 1M-Duo or Affymetrix 6.0). The mean call rate for the
discovery samples varied from 99.3% (mouthwash) to 99.5%
(blood). For the WTCCC2 data, we removed all samples listed in
the sample exclusions file provided by WTCCC. Exclusion criteria
included: cryptic relatedness between samples, gender mismatch,
low call rate, questionable identity based on previous genotyping,
outliers based on heterozygosity, outliers based on principal
component plots using HapMap samples, and outliers based on
mean A and B intensities on chromosome 22. We also removed all
SNPs in the WTCCC2 SNP exclusion files provided based on
these criteria: minor allele frequency ,1%, information ,0.975,
call frequency ,98% and plate association test p-value ,10
25.
Additionally, we removed SNPs with HWE p-value ,10
26, which
is a more stringent filter than that initially applied by the
WTCCC.
The replication samples were genotyped with TaqMan assays
(Applied Biosystems, Forest City, CA) using the 7900HT (Duke
University Center for Human Genetics, Durham, NC) and
OpenArray (HudsonAlpha Institute for Biotechnology, Huntsville,
AL) platforms. Genotypes were assigned using ABI’s Genotyper
software for OpenArray Taqman data, and SDS 2.4 for 7900HT
Taqman data. Samples with ,90% call rate on the OpenArray
platform or poor duplicate concordance were removed. SNPs
were removed based on call frequency ,90%, discordance
between duplicate samples, Mendelian inconsistencies in CEPH
trios, and discordance with previously-confirmed genotypes when
available.
Statistical analysis
For the discovery-phase analysis, we combined the markers and
genotypes from the Affymetrix 6.0 and Illumina 1M-Duo chips.
When a given marker was genotyped and passed QC on both
chips, we followed these steps to combine the genotypes: 1)
retained Illumina genotypes for symmetric (A/T or C/G) SNPs; 2)
performed Fisher’s exact test on a 362 table of genotype
frequencies by chip for each marker, and discarded SNPs with
p,0.001; 3) set any remaining discordant genotypes for a given
sample to be missing. We combined the Affymetrix 6.0 and
Illumina 1M-Duo genotypes for the WTCCC2 samples following
the same procedure with one exception: in step 2, due to the much
larger sample size, we used a x
2 test for different genotype
frequencies between the two chips. Finally, we used Fisher’s exact
test to test for genotype frequency differences between GENEVA
controls and WTCCC2 controls, and removed any markers with
p-value ,0.001.
ALS outcome. To test for genetic effects on the primary
endpoint of interest, ALS outcome, we restricted our analysis to
definite or probable ALS cases who received an initial ALS
diagnosis within the 24 months prior to Registry enrollment. We
also performed a sensitivity analysis by including other diagnoses
(possible ALS and PMA) and/or restricting analysis to cases
diagnosed within 12 months of Registry enrollment. Subjects with
diagnoses of PLS or PBP and those with longer lags (.24 months)
between diagnosis and study consent were excluded from the
ALS outcome analysis. Because the number of eligible GENEVA
controls was limited at the time of genotyping, we added the
publicly-available WTCCC2 controls in an effort to increase the
power of our analysis to detect moderate associations with ALS.
However, there may be important environmental or other
differences between the British non-veteran subjects in the
WTCCC2 sample and the US veterans in our study; for this
reason, we also performed analyses using the GENEVA controls
alone. We excluded all cases and controls with a first-degree
family history of ALS (self-reported or, for cases, determined by a
Registry neurologist) or a known SOD1 mutation. Finally, for the
purpose of comparison to previously published GWA studies and
to match the WTCCC2 controls, we restricted the analysis here
to self-reported non-Hispanic Caucasians. After these exclusions,
the sample used for ALS outcome analysis included 442 ALS
cases, 348 GENEVA controls and 5909 WTCCC2 controls (see
Table S2 for the number of samples meeting each exclusion
criterion).
Case-control analyses were carried out using unconditional
logistic regression, with genotypes coded additively based on the
number of copies of the minor allele. We included sex and
reference age (age at diagnosis for cases; age at interview for
controls) in models using GENEVA controls only. For models
including the WTCCC2 controls, we adjusted only for sex,
because age data were not available for these subjects at the time
of our analysis. For the discovery phase, we also adjusted all
models for potential population stratification in our sample by
including four components obtained from multi-dimensional
scaling analysis (MDS) in PLINK. The MDS components were
obtained based on a set of 84 k LD-pruned SNPs discussed in
Methods S3. Statistical analyses of the data were carried out using
Genome-Wide Screen of ALS in US Veterans
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was adapted from http://gettinggeneticsdone.blogspot.com/
2011/04/annotated-manhattan-plots-and-qq-plots.html.
For the replication phase, we performed unconditional logistic
regression on the replication samples alone (183 cases, 961
controls) and on the pooled set of samples (replication and
discovery) when SNPs were successfully genotyped on both sets of
samples. As with the discovery sample, we only considered non-
Hispanic Caucasians and restricted analysis to definite or probable
ALS cases who received an initial ALS diagnosis within the 24
months prior to study consent. Any genotypes that were discordant
between the discovery and replication phases were set to missing
for the combined analysis. All p-values reported in the discovery
and replication phases are unadjusted for multiple testing.
Survival. Our case group for survival analysis included all
non-Hispanic Caucasian cases with definite ALS or probable ALS,
regardless of the disease duration at the time of consent (n=639,
29.5% censored). For the survival analysis, we also excluded cases
who were already dependent on a ventilator at the time of study
enrollment (see Table S2). Using a Cox proportional hazards
regression model, we tested for genetic effects on the number of
months between diagnosis and either dependence on a ventilator
or death, whichever occurred first. We adjusted the model for left-
truncation in order to account for the fact that subjects had to
survive long enough to contribute a sample to the NRVA DNA
bank. All models contained an additive genotype term and
included age at diagnosis and sex as covariates. For the discovery
phase, the four components from the MDS analysis described
above were included as well. We categorized subjects as having
bulbar or non-bulbar onset; this variable did not meet the
proportional hazards assumption necessary for the model, so we
adjusted for site of onset using a stratified model instead of
including site of onset as a covariate. Survival analysis was
performed using PLINK (v1.06) and R (version 2.10.1), via a
PLINK plug-in.
For the replication phase, we performed a survival analysis
on the replication samples alone (n=118, 16.1% censored) and
on the pooled set of samples (replication and discovery) when
SNPs were successfully genotyped on both sets of samples. As
with the discovery sample, we restricted analysis to non-
Hispanic Caucasian cases diagnosed with definite or probable
ALS.
Selection of SNPs for replication genotyping
To account for the possibility that ALS-associated SNPs might
be enriched in the set of SNPs showing marginal (but not
genome-wide) significance, we selected SNPs for replication
genotyping using either a strict p-value criterion (p,1.0610
26)o r
a more lenient p-value criterion (p,1.0610
24) in the presence of
other evidence of association (previous independent studies or
consistent results across our sensitivity analyses). We examined
the genotype cluster plots for SNPs that met either criterion, and
only attempted to replicate SNPs that clustered well. In addition
to SNPs from the GWAS chips, we decided to genotype
additional SNPs in implicated genes/regions, because replication
may be observed at the level of a gene rather than a specific SNP.
We included common SNPs in coding regions or potential splice
sites from 20 selected genes, tagging SNPs from 5 selected genes,
and intragenic SNPs in moderate LD (r
2.0.5) with intergenic
SNPs of interest. Based on previously published GWA studies of
sporadic ALS, we also genotyped the discovery and replication
samples for variation in the genes DPP6 [7], ELP3 [3], ITPR2 [5],
and UNC13A [9], and for the intergenic SNP rs3849942 on
chromosome 9p21.2 [9,11]. We genotyped the specific implicated
SNPs in addition to common coding and possible splicing SNPs
in these genes. We also included a SNP in KIFAP3 previously
reported to be associated with survival [8]. The total number of
SNPs that were successfully genotyped in the replication samples
was 299 (286 selected for the ALS outcome phenotype, 13
selected for survival).
Table 1. Demographic and clinical characteristics of the discovery and replication samples.
Discovery
cases: ALS
outcome
Discovery
cases:
Survival
Discovery
controls
Replication
cases: ALS
outcome
Replication
cases:
Survival
Replication
controls
n 442 639 348 183 118 961
Male 435 (98.4%) 627 (98.1%) 331 (95.1%) 115 (62.8%) 80 (67.8%) 755 (78.6%)
Age (yrs, mean ± SD) 62.3610.2 60.4611.3 62.2610.7 59.4612.1 58.8612.2 63.5611.5
Veterans 442 (100%) 639 (100%) 348 (100%) 8 (4.4%) 12 (10.2%) 396 (41.2%)
Diagnosis Definite ALS 115 (26.0%) 200 (31.3%) - 183 (100%)* 118 (100%)* -
Probable ALS 327 (74.0%) 439 (68.7%) - -
Time from diagnosis
to study consent
0–12 months 293 (66.3%) 285 (44.6%) - 164 (89.6%) 98 (83.1%) -
12–24 months 149 (33.7%) 141 (22.1%) - 19 (10.4%) 16 (13.6%) -
24–36 months - 65 (10.2%) - - 1 (0.8%) -
.36 months - 148 (23.2%) - - 3 (2.5%) -
Bulbar onset 114 (25.8%) 130 (20.3%) - not available 35 (29.9%) -
Median onset to
diagnosis (mo)
11 11 - not available 9.1 -
Median survival after
diagnosis (mo)
24.0 (n=335) 29.0 (n=442) - 26.8 (n=144) 27.1 (n=99) -
*Definite/probable ALS breakdown was not available for all replication cases.
doi:10.1371/journal.pone.0032768.t001
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Discovery phase
After performing the sample quality control steps described in
the Methods, we obtained genotypes on at least one chip for 394
controls (95.9%) and 1142 cases (98.2%). Of these samples, 350
controls (88.8%) and 1104 cases (96.7%) passed QC on both
genotyping chips, yielding extremely high-density marker data.
After removing cases which did not meet the inclusion criteria for
analysis of ALS outcome or survival described above, our final
sample included 442 cases and 348 controls for the ALS outcome
analysis and 639 cases for the survival analysis. Demographic and
clinical characteristics of this discovery sample are shown in
Table 1. The veteran cases and controls had similar distributions
for military-specific characteristics (military branch with longest
service, length of service and deployment to major conflicts) [21].
After SNP quality control and removal of monomorphic SNPs,
we obtained genotypes for a total of 1,515,824 autosomal SNP
markers (88.1%) from either the Affymetrix 6.0 or Illumina 1M-
Duo genotyping chip. 1,280,579 of these markers (84.5%) also
met our minimum minor allele frequency (MAF) criterion
($3%).
Figure 1 shows Manhattan plots for the ALS outcome analysis,
both withandwithouttheWTCCC2controlsincluded.Nomarkers
metagenome-widesignificancethresholdofp,5.0610
28.Detailed
results of the most significant 25 SNPs from each analysis are shown
in Tables 2 and 3. Two genes, UNC13C and SETBP1, contain SNPs
in the top 25 of both analyses. The QQ plots for the two ALS
outcome analyses areshown in Figure 2. For the association analysis
including GENEVA controls only, there is a single relatively rare
SNP with an observed p-value smaller than expected, rs5762919 in
ZNRF3 (p=1.7610
27, MAF in cases=0.04). Unfortunately, this
SNP was not successfully genotyped in the WTCCC2 controls, so
we were unable to test for a consistent result with the larger set of
controls. The QQ plot for the analysis including the WTCCC2
controls deviates from the expected pattern under the null
hypothesis of genome-wide absence of association. We examined
whether this deviation might be due to residual population
stratification by including varying numbers of MDS axes (0, 4, 10,
and 20) in the logistic regression models and obtained similar QQ
Figure 1. Manhattan plots. a) ALS outcome with GENEVA controls only; b) ALS outcome with GENEVA and WTCCC2 controls included.
doi:10.1371/journal.pone.0032768.g001
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explanation for this observation might be the age, gender and
sample size differences between GENEVA and WTCCC2 controls;
another is our inability to adjust for age in the logistic regression
models that included the WTCCC2 controls.
Results from the survival GWAS are shown in Figure 3. Again,
no SNPs met a genome-wide significance threshold of
p,5.0610
28. The top 25 SNPs from the survival analysis are
shown in Table 4. There were five SNPs from the PARK2 gene in
the top ten, all of which are in strong linkage disequilibrium with
each other (r
2.0.85). The QQ plot derived from the survival
analysis is shown in Figure 4 and reflects a consistent trend of
observed p-values that are larger than expected. This attribute of
the QQ plot seems to be related to our exclusion of rare SNPs in
the survival analysis. When we included all polymorphic SNPs in
the analysis, regardless of MAF, the QQ plot conformed more
closely to the pattern expected under the genome-wide absence of
association (data not shown).
Replication and pooled analysis
After quality control of the replication samples, we obtained
genotypes for 299 SNPs on 278 cases (99.3%) and 1140 controls
(98.4%). Of these samples, 183 cases and 961 controls met the
inclusion criteria for the analysis of ALS outcome. In addition, 170
cases met the inclusion criteria for analysis of survival, but only
118 of these cases had data for site of onset and could be included
in the analysis. The replication SNPs were not all typed on the
same platform (two different OpenArray chips were used, along
with single-tube TaqMan assays) and quality control was
performed separately on each platform. For both ALS outcome
and survival, we conducted an analysis using the independent
replication samples alone, followed by a pooled analysis of all
samples.
The top ten most-significant results from the pooled analysis of
ALS outcome are given in Table 5. There is substantial overlap in
the results with and without the WTCCC2 controls, as seven
markers are in the top ten for both analyses. Although no SNPs
met a genome-wide significance threshold in the pooled analysis,
three SNPs produced statistically significant results in analysis of
the independent replication samples alone after adjustment for
multiple testing of 286 SNPs (p,1.75610
24): rs6080539 (177 kb
from PCSK2), rs7000234 (4 kb from ZNF704), and rs3113494
(13 kb from LOC100506746) (Table 5). Analogous results for the
top ten SNPs in the replication and pooled analysis of the survival
outcome are shown in Table 6. None of the SNPs tested in the
survival replication analysis showed evidence of association in the
replication analysis alone (p.0.05), which might partially be due
to the substantially smaller sample size.
Table 7 shows association results in our dataset for markers and
genes implicated in previous GWAS analyses of ALS outcome. For
Table 2. Discovery analysis: SNP association with ALS outcome using GENEVA controls only.
Minor allele frequency
Chr SNP Pos (build 36) Closest gene (distance)
Odds ratio
(95% CI) p Cases Controls
22 rs5762919 27693344 ZNRF3 0.3 (0.2, 0.5) 1.7E-07 0.04 0.10
4 rs1425419 124785414 LOC285419 (8 kb) 2.1 (1.5, 2.8) 1.9E-06 0.19 0.11
19 rs12327672 43742319 RYR1 0.4 (0.2, 0.5) 2.5E-06 0.04 0.11
7 rs2867161 67274777 STAG3L4 (851 kb) 0.4 (0.3, 0.6) 3.7E-06 0.06 0.13
7 rs17145184 67278550 STAG3L4 (855 kb) 0.4 (0.3, 0.6) 5.4E-06 0.07 0.13
7 rs7777387 22086962 RAPGEF5 (37 kb) 0.3 (0.2, 0.5) 5.6E-06 0.02 0.07
4 rs6816453 60844956 none within 1 Mb 0.5 (0.4, 0.7) 6.4E-06 0.13 0.23
10 rs7912496 87832985 GRID1 0.5 (0.4, 0.7) 7.6E-06 0.11 0.19
9 rs1796991 74507694 TMC1 0.5 (0.4, 0.7) 8.0E-06 0.14 0.23
4 rs7689003 44820582 GNPDA2 (397 kb) 0.6 (0.5, 0.8) 1.5E-05 0.27 0.38
15 rs11071021 52143583 UNC13C 0.6 (0.5, 0.8) 1.5E-05 0.36 0.47
18 rs17783459 40583074 SETBP1 2.1 (1.5, 3.0) 1.5E-05 0.15 0.07
5 rs4868146 171514050 STK10 0.6 (0.5, 0.8) 1.5E-05 0.32 0.42
4 rs4470701 52798649 SPATA18 (140 kb) 0.6 (0.5, 0.8) 1.7E-05 0.25 0.35
14 rs1950202 53909646 CDKN3 (24 kb) 0.6 (0.5, 0.8) 1.8E-05 0.25 0.35
4 rs10050211 60639119 none within 1 Mb 0.5 (0.3, 0.7) 1.9E-05 0.07 0.13
15 rs11071022 52149769 UNC13C 0.6 (0.5, 0.8) 1.9E-05 0.35 0.46
2 rs4972990 231987255 B3GNT7 (13 kb) 0.6 (0.5, 0.8) 2.1E-05 0.36 0.47
8 rs11204102 20137423 LZTS1 (11 kb) 1.7 (1.3, 2.1) 2.2E-05 0.36 0.25
15 rs1563755 27660863 FAM189A1 (11 kb) 0.6 (0.5, 0.8) 2.3E-05 0.28 0.38
15 rs8031323 27662042 FAM189A1 (12 kb) 0.6 (0.5, 0.8) 2.3E-05 0.28 0.38
2 rs2034413 231996393 B3GNT7 (22 kb) 0.6 (0.5, 0.8) 2.4E-05 0.29 0.39
2 rs2034412 231996305 B3GNT7 (22 kb) 0.6 (0.5, 0.8) 2.5E-05 0.29 0.39
2 rs16862162 174441451 SP3 (38 kb) 0.6 (0.5, 0.7) 2.6E-05 0.17 0.27
18 rs9959302 34316183 LOC647946 (725 kb) 0.6 (0.5, 0.8) 2.7E-05 0.31 0.41
doi:10.1371/journal.pone.0032768.t002
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the smallest p-value in the pooled analysis, but also the specific
SNPs found to be associated with ALS risk in previous studies. We
were unable to replicate the previously reported association of the
specific SNPs in 9p21.2 and ITPR2. SNP rs1541160 in KIFAP3,
which was implicated by the only other genome-wide analysis of
ALS survival [8], also did not show evidence for association in our
pooled dataset (HR=0.95, 95% CI=(0.82, 1.10), p=0.49). After
correcting for multiple testing (based on 57 markers selected from
genes previously reported to show association, p,8.8610
24), we
detected marginal association with rs6985069 near ELP3
(p=2.7610
24 with GENEVA controls only; p=4.8610
24 with
GENEVA+WTCCC2 controls). This is among the top 10 results
of the pooled analysis shown in Table 5, but is different from the
SNP previously reported as ALS-associated (rs13268593) [3].
Similarly, the specifically-implicated SNP rs10260404 in DPP6 did
not show any evidence for association, while rs17174381 in the
same gene had p-values of 0.005 (GENEVA controls only) and
4.4610
24 (GENEVA+WTCCC2 controls) in the pooled analysis.
Discussion
Our GWAS of US veterans did not identify any genetic
associations that reached genome-wide significance (p,5.0610
28)
for either ALS outcome or survival. After following up a smaller
number of SNPs, three SNPs were significantly associated with
ALS outcome in a replication-only analysis after adjusting for
multiple testing. Two of these markers fall outside the transcrip-
tional boundaries of their closest genes (PCSK2 and ZNF704), and
one is 13 kb from a hypothetical non-coding RNA
(LOC100506746). Several other SNPs with originally similar or
stronger associations (e.g. rs11071021 from UNC13C, which was in
the top 25 SNPs for the ALS outcome analysis with or without
WTCCC2 controls) did not meet criteria for statistical significance
in the replication phase.
Several factors may have contributed to this lack of intra-study
replication. Perhaps most importantly, veterans comprised all of
the cases and controls in our discovery phase analysis, but
comprised only 4% of the cases and 41% of the controls in our
replication sample. This also created a substantial difference in
gender distribution between the two samples. Because the higher
rate of ALS reported for US veterans may be partially due to
military-related environmental exposures and corresponding gene-
by-environment interactions, the heterogeneity in environmental
exposures between the discovery and replication samples could be
partly responsible for the lack of replication. In this case, a much
larger veteran-only replication sample would be required to detect
such interactions. Study design differences may also play a role:
Table 3. Discovery analysis: SNP association with ALS outcome using GENEVA+WTCCC2 controls.
Minor allele frequency
Chr SNP Pos (build 36)
Closest gene
(distance)
Odds ratio (95%
CI) P Cases
GENEVA
controls
WTCCC2
controls
13 rs9534003 44375190 NUFIP1 (36 kb) 1.7 (1.4, 2.1) 1.3E-06 0.18 0.12 0.12
15 rs11071021 52143583 UNC13C 0.7 (0.6, 0.8) 1.9E-06 0.36 0.47 0.42
20 rs6080544 16987959 PCSK2 (167 kb) 0.7 (0.6, 0.8) 2.6E-06 0.33 0.42 0.39
5 rs7707833 74323619 GCNT4 (35 kb) 0.7 (0.6, 0.8) 2.8E-06 0.33 0.40 0.39
20 rs6075164 16985876 PCSK2 (169 kb) 0.7 (0.6, 0.8) 2.8E-06 0.33 0.43 0.39
20 rs6075165 16986263 PCSK2 (168 kb) 0.7 (0.6, 0.8) 3.8E-06 0.33 0.43 0.39
2 rs6746842 118523065 CCDC93 (35 kb) 1.5 (1.2, 1.7) 4.0E-06 0.35 0.27 0.29
2 rs7571323 118549038 INSIG2 (13 kb) 1.5 (1.2, 1.7) 4.1E-06 0.35 0.27 0.29
2 rs2276695 118531338 INSIG2 (31 kb) 1.4 (1.2, 1.7) 4.2E-06 0.45 0.37 0.38
2 rs11688631 119296905 EN1 (19 kb) 1.5 (1.2, 1.7) 4.5E-06 0.49 0.42 0.45
14 rs6574039 71560768 RGS6 0.6 (0.5, 0.7) 5.1E-06 0.14 0.21 0.18
18 rs639964 40708686 SETBP1 0.7 (0.6, 0.8) 5.2E-06 0.38 0.46 0.44
16 rs12929572 60610083 CDH8 0.7 (0.6, 0.8) 5.2E-06 0.28 0.37 0.35
18 rs617459 40707045 SETBP1 0.7 (0.6, 0.8) 5.5E-06 0.38 0.46 0.44
3 rs2703029 54878655 CACNA2D3 1.4 (1.2, 1.7) 5.8E-06 0.48 0.43 0.45
18 rs7242525 34364676 LOC647946
(676 kb)
0.6 (0.5, 0.7) 6.0E-06 0.13 0.22 0.19
2 rs12466517 118546861 INSIG2 (16 kb) 1.4 (1.2, 1.7) 6.1E-06 0.45 0.37 0.38
5 rs6453104 74324825 GCNT4 (34 kb) 0.7 (0.6, 0.8) 6.7E-06 0.33 0.40 0.39
11 rs688858 87652911 CTSC (13 kb) 1.4 (1.2, 1.7) 7.4E-06 0.40 0.33 0.33
2 rs2161829 118573384 INSIG2 1.4 (1.2, 1.7) 9.2E-06 0.49 0.43 0.42
13 rs6561194 44374808 NUFIP1 (37 kb) 1.5 (1.2, 1.8) 1.3E-05 0.28 0.22 0.23
20 rs6080539 16977494 PCSK2 (177 kb) 0.7 (0.6, 0.8) 1.3E-05 0.30 0.40 0.36
20 rs7272442 15223538 MACROD2 1.4 (1.2, 1.7) 1.4E-05 0.46 0.44 0.48
2 rs6542427 118518151 CCDC93 (30 kb) 1.4 (1.2, 1.7) 1.4E-05 0.33 0.26 0.27
4 rs1425419 124785414 LOC285419 (8 kb)1.6 (1.3, 1.9) 1.5E-05 0.19 0.11 0.15
doi:10.1371/journal.pone.0032768.t003
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sample that included incident and prevalent cases, while the cases
in the replication study were derived from a clinic- or population-
based sample and were thus enriched for incident cases.
Therefore, patients analyzed in the discovery phase were, on
average, enrolled longer after diagnosis than patients analyzed in
the replication phase (Table 1), and patients who died within two
years of diagnosis may be under-represented in the discovery
sample. We accommodated this in our analysis by restricting the
ALS outcome analysis to incident cases and by adjusting the
survival analysis for the length-biased nature of the data. As shown
in Table 1, this phenotypic restriction led to similar observed
survival characteristics of the two groups of patients (median
survival 24.0 vs. 26.8 months for the patients included in the ALS
outcome analysis; 29.0 vs. 27.1 months for the patients included in
the survival analysis). In addition to the study design differences, it
is possible that diagnostic heterogeneity also contributes to the
difficulty of intra-study replication. The clinical criteria used by the
NRVA neurologists were carefully standardized and cross-
validated to minimize diagnostic heterogeneity within the
discovery sample. Such standardization was not possible in our
replication dataset, because these samples were independently
ascertained.
While none of the SNPs evaluated in this study reached
genome-wide significance, we noted several interesting genes as
potential candidates for further study. For example, results from
Figure 2. Quantile-quantile plots. a) ALS outcome with GENEVA controls only; b) ALS outcome with GENEVA and WTCCC2 controls included.
doi:10.1371/journal.pone.0032768.g002
Figure 3. Manhattan plot. Survival analysis of definite/probable ALS cases.
doi:10.1371/journal.pone.0032768.g003
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suggestive association with UNC13C which, like the previously
implicated UNC13A, is a homolog of the C. elegans gene UNC-13.
Both of these genes code for proteins with neurological effects.
Although not replicated, our discovery phase survival analysis
suggested a marginal association with variants in the PARK2 gene;
mutations in PARK2 are known to cause Parkinson’s disease
[42,43]. Finally, PCSK2 is an interesting candidate gene given
recent work on the potential relationship between ALS and
metabolic phenotypes such as hyperlipidemia, BMI and type 2
diabetes [44,45]. SNPs in PCSK2 have been shown to be associated
with type 2 diabetes in several ethnic populations [46–48]. We
again note that none of these genes contained markers that were
significant at a genome-wide level during the discovery phase of
this analysis, and present these genes only as plausible candidates
for study in independent populations.
Putting our GWAS in the context of previously published
genome-wide studies, we were unable to conclusively replicate the
previously-reported associations between ALS and ITPR2,
UNC13A or the 9p21.2 locus. However, at the level of the gene
rather than the specific previously implicated SNP, we observed
some evidence of association for ELP3 and DPP6. A previous
genome-wide survival analysis identified a SNP in KIFAP3 as
associated with increased survival of ALS patients. Our study
failed to replicate this association, consistent with another
independent study [49]. We note that, although our study is one
Figure 4. Quantile-quantile plot. Survival analysis of definite/
probable ALS cases.
doi:10.1371/journal.pone.0032768.g004
Table 4. Discovery analysis: SNP association with ALS survival time post-diagnosis.
Chr SNP pos (build 36) Closest gene (distance)
Hazard ratio
(95% CI) P
Minor allele
frequency
6 rs7740421 162890461 PARK2 0.5 (0.4, 0.7) 7.4E-06 0.08
4 rs6840169 83637534 TMEM150C 1.5 (1.2, 1.7) 7.8E-06 0.16
6 rs7757630 162860228 PARK2 0.5 (0.4, 0.7) 7.9E-06 0.07
6 rs7764218 162854134 PARK2 0.5 (0.4, 0.7) 8.6E-06 0.07
6 rs6904956 162865529 PARK2 0.5 (0.4, 0.7) 9.5E-06 0.08
6 rs564053 94874715 TSG1 (332 kb) 1.4 (1.2, 1.7) 9.6E-06 0.22
13 rs9509608 18196564 ANKRD20A9P (110 kb) 1.6 (1.3, 1.9) 9.7E-06 0.11
13 rs17263670 18162827 ANKRD20A9P (144 kb) 1.6 (1.3, 1.9) 1.0E-05 0.12
6 rs6931162 162863532 PARK2 0.5 (0.4, 0.7) 1.1E-05 0.08
15 rs873961 59135496 RORA 0.7 (0.6, 0.8) 1.4E-05 0.36
15 rs8037669 59137212 RORA 0.7 (0.6, 0.8) 1.7E-05 0.35
3 rs2581182 27899600 EOMES (161 kb) 0.6 (0.5, 0.8) 1.7E-05 0.12
10 rs4933508 91269359 SLC16A12 1.3 (1.2, 1.5) 2.0E-05 0.40
1 rs12024361 223544114 DNAH14 0.7 (0.6, 0.8) 2.2E-05 0.32
1 rs12042076 223544169 DNAH14 0.7 (0.6, 0.8) 2.2E-05 0.32
17 rs12951847 37132640 HAP1 1.5 (1.2, 1.8) 2.3E-05 0.15
4 rs632895 114207962 ANK2 0.6 (0.5, 0.8) 2.5E-05 0.14
1 rs488595 15558384 FHAD1 1.3 (1.2, 1.5) 3.1E-05 0.48
15 rs11632352 59145158 RORA 0.7 (0.6, 0.9) 3.2E-05 0.36
2 rs11885285 56202233 CCDC85A (63 kb) 1.4 (1.2, 1.6) 3.4E-05 0.23
10 rs11252748 4833378 AKR1E2 (25 kb) 1.4 (1.2, 1.6) 3.5E-05 0.22
22 rs9306510 46984975 MIR3201 (64 kb) 1.3 (1.2, 1.6) 3.6E-05 0.34
1 rs618465 54400418 CDCP2 (8 kb) 1.5 (1.2, 1.8) 3.8E-05 0.12
17 rs7213337 37132954 HAP1 1.5 (1.2, 1.8) 3.8E-05 0.14
1 rs10495234 223560206 DNAH14 0.7 (0.6, 0.8) 3.9E-05 0.30
doi:10.1371/journal.pone.0032768.t004
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underpowered to detect common variants with modest effects on
such a rare disease. For example, it would require approximately
2450 cases and an equal number of controls to have 80% power to
detect the magnitude of the effect of rs10260404 previously
described in the DPP6 gene [7].
Perhaps the most important factor contributing to the difficulty
of replication in independent populations is the underlying genetic
heterogeneity of the disease. Linkage studies of familial ALS have
implicated twelve loci and eight genes [50]. In addition to this
locus heterogeneity, there is also extensive allelic heterogeneity;
within the SOD1 gene, more than 125 non-synonymous coding
Table 5. Replication and pooled analysis: SNP association with ALS outcome, including and excluding WTCCC2 controls.
Discovery analysis Replication analysis Pooled analysis
Chr SNP pos (build 36)
Closest gene
(distance) OR (95% CI) P OR (95% CI) p OR (95% CI) p
Without WTCCC2 controls
4 rs4833346 127584779 FAT4 (951 kb) 1.5 (1.2, 1.9) 1.2E-04 1.1 (0.8, 1.5) 0.43 1.4 (1.2, 1.6) 2.1E-05
20 rs6075164 16985876 PCSK2 (169 kb) 0.7 (0.5, 0.8) 1.8E-04 0.8 (0.7, 0.9) 0.0016 0.7 (0.6, 0.8) 3.7E-05
20 rs6080539 16977494 PCSK2 (177 kb) 0.6 (0.5, 0.8) 1.1E-04 0.7 (0.6, 0.8) 5.0E-05* 0.7 (0.6, 0.8) 5.1E-05
8 rs7000234 81699669 ZNF704 (4 kb) 2.0 (1.3, 3.1) 8.6E-04 1.8 (1.4, 2.4) 6.1E-05* 1.7 (1.3, 2.3) 1.5E-04
20 rs6080544 16987959 PCSK2 (167 kb) 0.7 (0.5, 0.8) 2.0E-04 1.0 (0.8, 1.4) 0.78 0.7 (0.6, 0.9) 1.9E-04
4 rs3113494 88051625 LOC100506746
(13 kb)
0.7 (0.6, 0.8) 1.9E-04 0.7 (0.6, 0.9) 9.6E-05* 0.8 (0.6, 0.9) 2.0E-04
11 rs2278170 4453422 OR52K1 (13 kb) 0.7 (0.5, 0.8) 5.5E-04 0.7 (0.6, 0.9) 8.0E-04 0.7 (0.6, 0.9) 2.4E-04
6 rs1190270 105731108 POPDC3 0.5 (0.3, 0.7) 1.8E-04 0.6 (0.4, 0.8) 4.0E-04 0.6 (0.4, 0.8) 2.7E-04
8 rs6985069 28142007 ELP3 (37 kb) 0.7 (0.6, 0.9) 6.0E-03 0.7 (0.6, 0.9) 3.3E-04 0.7 (0.6, 0.9) 2.7E-04
11 rs9633905 4453189 OR52K1 (13 kb) 0.7 (0.5, 0.8) 5.9E-04 0.8 (0.6, 0.9) 8.9E-04 0.7 (0.6, 0.9) 4.3E-04
With WTCCC2 controls
4 rs3113494 88051625 LOC100506746
(13 kb)
0.7 (0.6, 0.9) 2.8E-04 0.7 (0.6, 0.9) 9.6E-05* 0.7 (0.6, 0.8) 9.0E-07
11 rs2278170 4453422 OR52K1 (13 kb) 0.8 (0.6, 0.9) 0.0020 0.7 (0.6, 0.9) 8.0E-04 0.7 (0.6, 0.8) 6.7E-06
3 rs17253119 54905813 CACNA2D3 0.6 (0.5, 0.9) 0.0028 0.7 (0.5, 0.9) 0.011 0.6 (0.5, 0.8) 1.8E-05
6 rs1190270 105731108 POPDC3 0.5 (0.3, 0.7) 1.3E-04 0.6 (0.4, 0.8) 4.0E-04 0.6 (0.4, 0.7) 3.6E-05
18 rs7242525 34364676 LOC647946 (676 kb) 0.6 (0.5, 0.7) 6.0E-06 0.7 (0.6, 0.9) 0.0043 0.7 (0.5, 0.8) 1.1E-04
4 rs4833346 127584779 FAT4 (951 kb) 1.4 (1.2, 1.6) 9.8E-05 1.1 (0.8, 1.5) 0.43 1.3 (1.1, 1.5) 1.7E-04
20 rs6080539 16977494 PCSK2 (177 kb) 0.7 (0.6, 0.8) 1.3E-05 0.7 (0.6, 0.8) 5.0E-05* 0.8 (0.7, 0.9) 1.9E-04
8 rs7000234 81699669 ZNF704 (4 kb) 1.7 (1.3, 2.2) 2.4E-04 1.8 (1.4, 2.4) 6.1E-05* 1.5 (1.2, 1.9) 2.2E-04
20 rs6075164 16985876 PCSK2 (169 kb) 0.7 (0.6, 0.8) 2.8E-06 0.8 (0.7, 0.9) 0.0016 0.8 (0.7, 0.9) 2.7E-04
4 rs12651081 88103790 AFF1 0.9 (0.7, 1.0) 0.060 0.8 (0.6, 1.0) 0.10 0.8 (0.7, 0.9) 3.1E-04
*Significant in replication-only analysis after Bonferroni adjustment (p,1.8610
24).
doi:10.1371/journal.pone.0032768.t005
Table 6. Replication and pooled analysis: SNP association with ALS survival.
Discovery analysis Replication analysis Pooled analysis
Chr SNP pos (build 36)
Closest gene
(distance)
Hazard ratio
(95% CI) P
Hazard ratio
(95% CI) p
Hazard ratio
(95% CI) p
4 rs6840169 83637534 TMEM150C 1.5 (1.2, 1.7) 7.8E-06 1.2 (0.8, 1.9) 0.40 1.4 (1.2, 1.6) 3.9E-05
6 rs564053 94874715 TSG1 (332 kb) 1.4 (1.2, 1.7) 9.6E-06 1.1 (0.7, 1.6) 0.62 1.4 (1.2, 1.6) 5.5E-05
15 rs873961 59135496 RORA 0.7 (0.6, 0.8) 1.4E-05 1.2 (0.9, 1.6) 0.31 0.8 (0.7, 0.9) 7.2E-05
15 rs11632352 59145158 RORA 0.7 (0.6, 0.9) 3.2E-05 1.1 (0.8, 1.5) 0.63 0.8 (0.7, 0.9) 7.5E-05
6 rs7764218 162854134 PARK2 0.5 (0.4, 0.7) 8.6E-06 1.1 (0.7, 1.8) 0.65 0.6 (0.5, 0.8) 1.5E-04
6 rs7757630 162860228 PARK2 0.5 (0.4, 0.7) 7.9E-06 1.1 (0.7, 1.7) 0.72 0.6 (0.5, 0.8) 1.5E-04
15 rs8037669 59137212 RORA 0.7 (0.6, 0.8) 1.7E-05 1.3 (0.9, 1.9) 0.11 0.8 (0.7, 0.9) 1.6E-04
6 rs7740421 162890461 PARK2 0.5 (0.4, 0.7) 7.4E-06 1.2 (0.7, 2) 0.56 0.6 (0.5, 0.8) 2.5E-04
20 rs6027005 57632613 PHACTR3 1.7 (1.3, 2.3) 2.0E-04 0.8 (0.2, 3.3) 0.75 1.7 (1.3, 2.2) 4.1E-04
6 rs6904956 162865529 PARK2 0.5 (0.4, 0.7) 9.5E-06 0.9 (0.7, 1.4) 0.76 0.7 (0.5, 0.8) 5.1E-04
doi:10.1371/journal.pone.0032768.t006
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exists in sporadic ALS, meta-analysis of many association studies
will be needed to generate the very large sample sizes required to
reliably identify causative variants. Although results from a
number of GWA studies in ALS have not been successfully
replicated, two recent studies did replicate an association with a
common hexanucleotide repeat in the 9p21 region that accounts
for a large proportion of familial and sporadic disease in European
and North American populations [17,18]. This region was initially
identified through a genome-wide screen [9]. Although a risk
haplotype containing expanded repeats in this region is well-
tagged by a particular SNP (rs3849942), the association signal
from analysis of the repeats is much stronger than the association
signal from the SNP [17], which underscores the difficulty of
identifying causal variants other than SNPs using chip-based
GWAS analysis. Given the known genetic heterogeneity in ALS
and the possibility that multiple rare, highly-penetrant variants
may account for a greater proportion of currently unexplained
disease than common variants with lower penetrance, exome or
whole genome sequencing may prove to be more successful than
GWAS studies in revealing the genetic underpinnings of this
devastating disease.
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